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ABSTRACT 130 
BACKGROUND: Spontaneous portosystemic shunts (SPSS) frequently develop in 131 
liver cirrhosis. Recent data suggested that presence of a single large SPSS is 132 
associated with complications, especially overt hepatic encephalopathy (oHE). 133 
However, presence of >1 SPSS is common. This study evaluates the impact of total 134 
cross-sectional SPSS area (TSA) on outcome of patients with liver cirrhosis. 135 
METHODS: In this retrospective international multicentric study, computed 136 
tomography (CT) scans of 908 cirrhotic patients with SPSS were evaluated for TSA. 137 
Clinical and laboratory data were recorded. Each detected SPSS radius was 138 
measured and TSA calculated. 1-year survival was primary and acute 139 
decompensation (oHE, variceal bleeding, ascites) secondary endpoint. 140 
RESULTS: 301 patients (169 male) were included in the training cohort. 30% of all 141 
patients presented >1 SPSS. TSA cut-off of 83 mm2 was determined to classify 142 
patients with small or large TSA (S-/L-TSA). L-TSA patients presented higher MELD 143 
(11 vs. 14) and more commonly history of oHE (12% vs. 21%, p<0.05). During follow 144 
up L-TSA patients developed more oHE episodes (33% vs. 47%, p<0.05) and 145 
showed lower 1-year survival than S-TSA (84% vs. 69%, p<0.001). Multivariate 146 
analysis identified L-TSA (HR 1.66, 1.02-2.70, p<0.05) as independent predictor of 147 
mortality. An independent multicentric validation cohort of 607 patients confirmed L-148 
TSA patients with lower 1-year survival (77% vs. 64%, p<0.001) and more oHE 149 
development (35% vs. 49%, p<0.001) than S-TSA. 150 
CONCLUSION: This study suggests that TSA >83mm2 increases the risk for oHE 151 
and mortality in liver cirrhosis. Our results may have impact on clinical use of 152 
TSA/SPSS for risk stratification and clinical decision-making considering 153 
management of SPSS.  154 
Word count:  258 155 
 156 
 157 
 158 
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 159 
 160 
Lay Summary 161 
Prevalence of spontaneous portosystemic shunt (SPSS) is higher in patients with 162 
more advanced chronic liver disease. Presence of more than one SPSS is common 163 
in advanced chronic liver disease and associated with development of hepatic 164 
encephalopathy. This study shows that total cross-sectional SPSS area (rather than 165 
diameter of the single largest SPSS) predicts survival in patients with advanced 166 
chronic liver disease. The cut-off of the total cross-sectional SPSS area associated 167 
with worse survival corresponds to a single shunt of more than 10mm diameter. This 168 
study may have impact on clinical use of TSA/SPSS for risk stratification and clinical 169 
decision-making considering management of SPSS.  170 
 171 
 172 
 173 
 174 
  175 
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INTRODUCTION 176 
In the course of liver cirrhosis the development of portal hypertension is a major 177 
driver of complications and therefore a frequent cause of acute decompensations 178 
(AD) (1,2). AD may lead to a systemic inflammatory response and progress to acute-179 
on-chronic liver failure (ACLF), a syndrome with high short-term mortality (3–6). Also 180 
in cirrhotic patients, portal hypertension is the driver of spontaneous portosystemic 181 
shunts (SPSS) development.  182 
The association of SPSS or surgical/interventional shunting with hepatic 183 
encephalopathy (HE) is well-known and the first embolizations of SPSS as an option 184 
to limit complications of portal hypertension have been reported more than 30 years 185 
ago (7–9). However, since then few reports on the role of SPSS in cirrhosis and their 186 
possible treatment have been published (10–14). A large multicentric study confirmed 187 
the association of a single large (diameter > 8 mm) SPSS with the occurrence of 188 
hepatic encephalopathy (15). Other  reports have also demonstrated that 189 
interventional embolization of SPSS can improve refractory hepatic encephalopathy 190 
and liver failure in selected patients (16,17). Since the procedure of SPSS-191 
embolization is invasive and in many cases requires direct portal venous access, 192 
there is an open discussion to whether or when the procedure is indicated (12,18–193 
20). As a result, in current guidelines recommendations for the management of SPSS 194 
are still missing (2,21–23).  195 
The presence of SPSS and especially their cumulative size has not been associated 196 
with hard endpoints such as survival. From a pathophysiological point of view the 197 
total cross-sectional shunt area of a SPSS (or cumulative area of several SPSS) may 198 
reflect the portosystemically shunted blood volume (24) more accurate than SPSS 199 
diameter. With the improved quality of imaging, especially in computed tomography 200 
Praktiknjo, Simón-Talero et al.        Large total SPSS area predicts mortality in liver cirrhosis 
8 
 
(CT), the detection of SPSS in clinical routine is feasible and reliable. This present 201 
study aimed to evaluate the role of the combined cross-sectional area of all SPSS, as 202 
a surrogate marker of portosystemically shunted blood volume, in the natural course 203 
of patients with liver cirrhosis. 204 
 205 
METHODS 206 
Study population 207 
For this retrospective study, a total of 301 patients from the University Hospital of 208 
Bonn were identified for inclusion as training cohort. Inclusion criteria were age of 18 209 
years or older, diagnosis of cirrhosis (clinical, radiologic or histologic) and SPSS of at 210 
least 5 mm of diameter in CT scans between October 2006 and April 2016. Since 211 
precision to measure SPSS diameter was needed, a minimum diameter of >5 mm 212 
was considered by our radiologist to provide accurate SPSS size. Date of CT scan 213 
was defined as baseline. Exclusion criteria were presence of hepatocellular 214 
carcinoma (HCC) beyond Milan criteria, previous transjugular intrahepatic 215 
portosystemic shunt (TIPS) or surgical shunt, any medical condition with expected 216 
survival fewer than 6 months, presence of neurologic, or psychiatric disorder 217 
preventing a proper hepatic encephalopathy evaluation and absence of critical 218 
information in the medical history (15). The validation cohort was formed of a total of 219 
607 consecutive patients, identified between 2010 and 2015 with the same selection 220 
criteria as the training cohort from the rest of the participating centres in the 221 
previously published multicenter study (15). Although excluding small SPSS of less of 222 
5 mm was not an original criterion in this prior multicenter study, it was applied to the 223 
validation cohort for consistency. In all patients, cross-sectional area of all detectable 224 
SPSS was assessed and calculated in CT scans. Clinical and laboratory blood 225 
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analysis data was followed up until end of follow up, death or liver transplantation 226 
(LT).  227 
Primary endpoint was 1-year survival and secondary endpoints were acute 228 
decompensations (hepatic encephalopathy (HE), variceal bleeding and ascites) 229 
during follow up. 230 
The local ethics committee of the of the participating centres approved the study. The 231 
study was performed in accordance with the Helsinki Declaration. 232 
Assessment of SPSS parameters 233 
All CT scans were reviewed by radiologists with expertise in liver diseases. SPSS 234 
were defined as previously described (15). Radiological study protocol shown in 235 
supplemental material 1. All CT scans were screened for any spontaneous 236 
portosystemic shunt (SPSS) by scrolling through the abdominal CT scan in axial 237 
plane. If available, portal venous phase was preferred. In particular, it was looked for 238 
any additional veins leaving inferior vena cava, portal vein, splenic vein, right/left 239 
renal vein and superior/inferior mesenteric vein. When detecting SPSS, it was 240 
verified by coronal and sagittal plane. 241 
Following, the position of the SPSS with the largest diameter was identified. At this 242 
position the short-axis diameter was reconstructed and measured between both walls 243 
of the vessel.  244 
The 607 CT scans from the validation cohort were reviewed again to measure the 245 
total shunt area (TSA) for the present study by the same radiologists who evaluate 246 
them in the prior study (15). We have chosen to measure the cross-sectional area 247 
instead of the diameter because more than one SPSS can occur in patients with liver 248 
cirrhosis and portal hypertension (15). Though the sum of diameters of all SPSS can 249 
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be the same, the sum of cross-sectional areas can be vastly different as shown in 250 
supplemental figure 1. We hypothesized, that cross-sectional area (TSA) reflects the 251 
shunted blood volume better than diameters. For each SPSS we calculated the area 252 
by the formula πr2. All SPSS areas were then summed up to calculate total SPSS 253 
area (TSA) for each patient.  254 
The diameters of the SPSS were measured twice (initial data were collected from the 255 
previous study by Simón-Talero et al (15); for the current work, all the CTs were 256 
reviewed again by the same expert radiologists). Therefore, the intra-rater variability 257 
of the measurement has been calculated, with an intraclass correlation coefficient 258 
(ICC) of 0.95 (95% CI 0.94-0.96). 259 
Esophageal and gastric varices were documented, but not measured. Rectal varices 260 
were neither measured nor documented. We decided so, because in both cases 261 
mostly the shunts are more of a network than a single vessel that can be determined. 262 
Statistical analysis 263 
We performed descriptive statistics for all variables. Non-parametric testing was used 264 
to compare different groups when suitable. Paired non-parametric testing was used 265 
to compare data of baseline and follow up of the same patients. Correlation of metric 266 
variables was performed using Spearman’s correlation. For the selection of cut off 267 
values of TSA receiver-operating characteristics (ROC) analysis with 1-year survival 268 
as end point was calculated. To examine the impact of TSA on survival we used 269 
Kaplan-Meier curve with log-rank test. Univariate and multivariate risk factor analyses 270 
were performed with Cox regression for 1-year mortality and episodes of hepatic 271 
encephalopathy as end points. Univariate analysis included general characteristics 272 
(age, sex) and clinical conditions (hepatic encephalopathy, hepatorenal syndrome, 273 
ascites, spontaneous bacterial peritonitis) as well as prognostic score (MELD) and 274 
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laboratory parameters (Na, creatinine, bilirubin, INR) at baseline. Multivariate 275 
analysis included all values with p<0.05 from univariate Cox regression. To avoid 276 
multicollinearity calculated scores, such as MELD, were not entered simultaneously 277 
with their components and scores with overlapping components (Child-Pugh) were 278 
not entered simultaneously as well. Continuous variables are presented as median 279 
(range), unless otherwise specified. Categorical variables are presented as absolute 280 
cases and/or percentage. The intra-rater reliability was calculated using the interclass 281 
correlation coefficient. All data was analyzed using SPSS (version 24, IBM, Armonk, 282 
NY, USA) or R statistics (version 3.4.4, The R Foundation). 283 
  284 
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RESULTS 285 
General patient characteristics  286 
Training cohort 287 
Of all 908 patients, 301 patients from University of Bonn were included in the training 288 
cohort (figure 1). Of those 169 patients were male. Median age at baseline was 56 289 
(28-85) years. Alcohol was the most common etiology of cirrhosis (57% of patients), 290 
while 20% of patients had chronic viral hepatitis B and/or C infection. Other etiologies 291 
were present in 23 % of patients. Most of the patients were decompensated (Child-292 
Pugh B or C in 59%) with 64% of the patients exhibiting ascites at time of CT scan; 293 
16% had experienced at least one hepatic encephalopathy episode and 26% had 294 
hepatic encephalopathy at baseline. A history of variceal bleeding was present in 295 
28% of the patients. Median MELD score was 13 (6-40). Detailed general 296 
characteristics are displayed in table 1. Of note, high platelet counts >250 x109/l were 297 
found in 26 patients. Of those 9 patients had infection, 3 recent bleeding and 2 iron 298 
deficiency as likely causes for high platelet counts. Median follow up time was 15 (0-299 
117) months. Median time from diagnosis of liver cirrhosis to CT scan was 17 months 300 
(0-1322). Indications for CT scans are displayed in supplemental table 1. 301 
Follow up data on survival status was available in 254 patients (table 1). During 302 
follow up MELD decreased slightly, while other prognostic scores (MELD-Na, Child-303 
Pugh) did not change significantly. Compared to baseline the rate of patients 304 
developing hepatorenal syndrome (23%) and episodes of hepatic encephalopathy 305 
(38%) increased significantly. The rate of patients with ascites and variceal bleeding 306 
did not change significantly (table1). In total, 23 patients were treated with TIPS (16 307 
for refractory ascites, 7 for variceal hemorrhage) during follow up. Detailed analysis 308 
of number of TIPS and LT in relation to MELD is shown in supplemental table 2. 309 
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SPSS characteristics 310 
In the training cohort of 301 patients, a total of 392 SPSS were identified. Most 311 
patients had one single SPSS (70%), while almost one third (30%) was diagnosed 312 
with more than one SPSS (table 1).  313 
The most common SPSS types were para-umbilical shunts representing 57% of all 314 
shunts, followed by splenorenal shunts in 32%, mesocaval 5% and 2% each for 315 
gastrorenal and adrenal vein. Infero-mesenterico-caval, right renal vein and 316 
mesorenal shunts were each found in only 1% of SPSS.  317 
 318 
Validation cohort 319 
A total of 607 patients from 11 participating centres were included in the validation 320 
cohort (supplemental table 3, figure 1). Median age was 58 (18-87) years with 65% 321 
male patients. Alcohol was the most common etiology of cirrhosis (43%), while 27% 322 
had viral hepatitis. Most patients (66%) had decompensated cirrhosis (Child-Pugh B 323 
or C); 53 % of the patients exhibiting ascites at time of CT scan and 30% had 324 
experienced at least one hepatic encephalopathy episode and 25% had hepatic 325 
encephalopathy at baseline. A history of variceal bleeding was present in 25% of the 326 
patients. Median MELD score was 13 (6-37). Detailed general characteristics are 327 
displayed in table 2. 328 
Follow up data is shown in table 2. Briefly, similar to the training cohort the rate of 329 
patients developing hepatorenal syndrome (11%), as well as episodes of hepatic 330 
encephalopathy (42%) increased significantly compared to baseline. The rate of 331 
ascites and variceal bleeding did not change significantly (table 2). 332 
SPSS characteristics 333 
Praktiknjo, Simón-Talero et al.        Large total SPSS area predicts mortality in liver cirrhosis 
14 
 
In the validation cohort of 607 patients, 754 SPSS were identified. The majority of 334 
patients had one single SPSS (79%), while 21% had multiple SPSS (table 2). 335 
Splenorenal shunt was the most common type with 41%, followed by para-umbilical 336 
shunt in 35%. Mesocaval shunt was present in 7%, gastrorenal in 6%, infero-337 
mesenterico-caval in 3% and mesorenal in 1% of SPSS. 338 
 339 
  340 
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Patient stratification by total SPSS area (TSA) 341 
A receiver operating characteristics analysis of TSA with 1-year survival as endpoint 342 
was performed and an AUC of 0.609 (CI 0.531-0.687, p=0.007) was calculated. The 343 
optimal cut-off value for the training cohort was found at 83 mm2 (sensitivity 55.7%, 344 
specificity 66.8%, positive predictive value 39.0%, negative predictive value 79.9%; 345 
supplemental table 4). Patients with TSA above 83 mm2 (corresponding to a single 346 
shunt of 10mm diameter) were classified as large TSA (L-TSA) and patients with TSA 347 
below 83 mm2 were classified as small TSA (S-TSA). Median TSA was 59 mm2 (6-348 
881). Patients with S-TSA had a median TSA of 35 mm2 (6-82) and L-TSA of 141.46 349 
mm2 (83-881) (table 3). In total, 180 patients were classified as S-TSA (60%) and 350 
121 as L-TSA (40%). There were no significant differences in type of SPSS between 351 
S-TSA and L-TSA patients. Time between diagnosis of cirrhosis and CT scan was 352 
not significantly different between S-TSA and L-TSA patients (15 (0-1322) vs. 24 (0-353 
369) months, p=0.503). 354 
L-TSA patients had significantly higher rates of multiple SPSS, as well as higher 355 
MELD scores (14 vs. 11). Moreover, L-TSA patients had higher rates hepatic 356 
encephalopathy episodes in their medical history (table 3). In follow up MELD (12 vs. 357 
15, p<0.01) and MELD-Na (13 vs. 16, p<0.05) score remained significantly higher in 358 
L-TSA compared to S-TSA group. CLIF-C AD score was not significantly different. 359 
Additionally, Child-Pugh score (6 vs 7, p<0.05) in follow up showed higher values for 360 
L-TSA. This mainly derives from serum albumin levels being significantly lower in L-361 
TSA (35 vs 31 g/L, p<0.001) (table 3). There were no significant differences 362 
detectable in term of hepatorenal syndrome, ascites and infections. 363 
 364 
 365 
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L-TSA is associated with hepatic encephalopathy  366 
Training cohort 367 
L-TSA patients had significantly higher risk of developing hepatic encephalopathy as 368 
shown in cumulative hazard function for hepatic encephalopathy in figure 2a. Blood 369 
ammonia levels were available in 154 patients. Median blood ammonia level was 65 370 
µmol/l (9-260). Patients were divided into high (>65 µmol/l) and low (≤65 µmol/l) 371 
ammonia levels. L-TSA patients showed higher rates (57%) of high ammonia levels 372 
than S-TSA patients (42%) (supplemental table 5). 373 
Validation cohort 374 
In the validation cohort clinical but no blood parameters were available at follow up 375 
(table 4). Importantly, the significantly higher rates of episodes of hepatic 376 
encephalopathy were confirmed as shown in figure 2b. 377 
Large TSA is an independent risk factor for 1-year mortality  378 
Training cohort 379 
1-year survival data was available in 253 patients. Figure 3a shows Kaplan-Meier 380 
curve for 1-year mortality. Kaplan-Meier curve for 1-year survival excluding patients 381 
with high platelet counts showed similar results (supplemental figure 2). L-TSA 382 
patients had a significantly higher mortality compared to S-TSA patients (p<0.001). 383 
Most deaths are attributed to infection (63%%). Hepatocellular carcinoma and liver 384 
failure attributed 10% and 13 % of deaths, respectively. 6% died of bleeding and 385 
cardiovascular events (supplemental table 6). 386 
Univariate Cox regression to identify risk factors for 1-year mortality was performed. 387 
This revealed besides the expected prognostic MELD score, creatinine, bilirubin and 388 
INR also hepatorenal syndrome, hepatic encephalopathy, spontaneous bacterial 389 
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peritonitis, ascites and L-TSA at baseline as dependent predictors of survival. 390 
Multivariate Cox regression identified L-TSA alongside MELD, hepatic 391 
encephalopathy, hepatorenal syndrome and ascites as independent risk factors for 1-392 
year survival (table 5).  393 
A different model with TSA as continuous variable was calculated, which confirmed 394 
TSA (as continuous variable) as an independent predictor of 1-year survival 395 
(supplemental table 7).  396 
Validation cohort 397 
In order to validate these results, the validation cohort was stratified for TSA. A total 398 
of 312 patients were classified as S-TSA (51%) and 295 as L-TSA (49%). L-TSA 399 
patients showed significantly higher MELD and Child-Pugh score. There were no 400 
significant differences in type of SPSS between S-TSA and L-TSA patients. 401 
Moreover, L-TSA had higher rates of hepatic encephalopathy episodes at baseline 402 
and in their medical history (table 4). Survival data was available in 604 patients. 403 
Figure 3b shows Kaplan-Meier curve for 1-year mortality. L-TSA patients had a 404 
significantly higher mortality compared to S-TSA patients (p<0.001). Kaplan-Meier 405 
curve for 1-year survival excluding patients with high platelet counts showed similar 406 
results (supplemental figure 3). 407 
Most deaths in the validation cohort were attributed by liver failure (36%), infection 408 
(19%) and HCC (12%). 6% died of bleeding. 27% died of other or unknown reasons 409 
(supplemental table 8). 410 
Univariate Cox regression to identify risk factors for 1-year mortality was performed. 411 
In this validation cohort prognostic markers such as MELD, creatinine, bilirubin and 412 
INR, also with hepatorenal syndrome, hepatic encephalopathy, spontaneous 413 
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bacterial peritonitis, ascites and TSA at baseline were dependent predictors of 414 
survival. Multivariate Cox regression confirmed TSA and MELD as independent 415 
predictors of 1-year mortality. Moreover, age, hepatorenal syndrome and ascites 416 
were shown as independent risk factors for 1-year survival (table 6). 417 
In an alternative model using TSA as a continuous variable, TSA was still an 418 
independent predictor of 1-year mortality, suggesting a linear relationship 419 
(supplemental table 9). 420 
To further investigate the impact of TSA on survival in relation liver function, we 421 
divided the whole cohort in tertials according to MELD (6-9, 10-13, 14-40) like in our 422 
previous study (15). The rates of 1-year mortality were higher in the L-TSA group and 423 
significant in MELD groups 6-9 and 14-40 (supplemental table 10). 424 
SPSS and TSA distribution 425 
In our recent multicenter study (15), a stratification of patients according to SPSS 426 
diameter (8mm cut-off) did not show significant differences in survival between S-427 
SPSS (<8mm) and L-SPSS (≥8mm). Therefore, we investigated the distribution of S-428 
/L-SPSS and S-/L-TSA of the whole cohort. The results are shown in supplemental 429 
figure 4. In total, 35% of patients were classified S-SPSS and S-TSA, 0.3% S-SPSS 430 
and L-TSA, 19% L-SPSS and S-TSA and 46% L-SPSS and L-TSA. This suggests 431 
mostly concordant classification between S-SPSS and S-TSA. However, a 432 
substantial fraction (19%) of patients with L-SPSS are classified as S-TSA as well. 433 
Kaplan-Meier survival curve shows no significant difference in survival between S-434 
SPSS and L-SPSS patients (supplemental figure 5), confirming our previous study 435 
(15). Importantly, Kaplan-Meier survival analysis of only L-SPSS patients showed a 436 
highly significant difference between patients classified as S-TSA and L-TSA, 437 
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demonstrating that TSA classification clearly outperforms classification by SPSS 438 
diameter (supplemental figure 6). 439 
We performed a Cox regression model for 1-year survival with L-SPSS instead of L-440 
TSA to evaluate the predictive value of presence of L-SPSS. In both the training and 441 
validation cohort SPSS was not significant in multivariate analysis. In the validation 442 
cohort, SPSS was not significant in the univariate analysis either (supplemental table 443 
11 and 12). 444 
 445 
DISCUSSION 446 
This study demonstrates for the first time that portosystemic shunting is associated 447 
with increased mortality in cirrhotic patients independently of severity of liver disease 448 
using a large single center training and a large multicentric international validation 449 
cohort.  450 
These results build up on the previously reported data on the influence of the 451 
diameter of largest SPSS, where a clear association with the risk of occurrence of 452 
complications of liver cirrhosis was demonstrated (15). This study confirms those 453 
results, which underlines the robustness of TSA. Another aspect to support the 454 
plausibility of our data is the fact, that L-TSA was found in more advanced stages of 455 
liver cirrhosis, reflected by higher MELD scores, which is in line with previous reports 456 
(15,25). One might argue, that retrieving and calculating the cross-sectional area of 457 
every SPSS is costly and more time consuming compared to just measuring the 458 
diameter of the largest SPSS. However, having a single SPSS of 10 mm diameter or 459 
more qualifies for L-TSA but not multiple SPSS with an added diameter of 10mm. 460 
This situation of multiple SPSS is present in one third of the presented large cohort. 461 
The present study demonstrates that the complete shunting volume, which might be 462 
better reflected by TSA, gives independent insight in the progression of liver disease 463 
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and outcome of cirrhotic patients. This hypothesis is supported by this study because 464 
the size of TSA has an independent impact on survival in cirrhotic patients, which 465 
could not be demonstrated for diameter of the single largest SPSS (< 8 mm vs ≥ 8 466 
mm) (15). This is especially impactful because, as shown in our and other cohorts, 467 
about one third of the patients have more than one SPSS (15,26,27). Since this study 468 
demonstrates TSA as a risk factor for survival independent of MELD, an 469 
incorporation of TSA in MELD (TSA-MELD) could improve patient’s risk stratification 470 
and should be evaluated in future research. 471 
The association of hepatic encephalopathy and SPSS is well established (7,15,28–472 
31). This association with hepatic encephalopathy is not only apparent for 473 
spontaneous shunts but also for therapeutically implanted shunts (e.g. TIPS and 474 
surgical shunts), where episodes of hepatic encephalopathy occur in up to 50% of 475 
patients (31–33). Although only shown in few cohorts, the deleterious effect of 476 
shunting seems to be additive by the number shunts (spontaneous and intentional) 477 
as the presence of SPSS and TIPS has been shown to be associated with more 478 
complications than TIPS alone (34,35). Growing evidence has been published that 479 
suggests less complications after TIPS by using smaller diameter stents or dilatation 480 
of stents smaller than the nominal diameter, suggesting a beneficial effect of less 481 
shunt volume (36–40).  482 
Regarding other decompensating events, we were unable to find a significant 483 
difference in variceal bleeding, hepatorenal syndrome or spontaneous bacterial 484 
peritonitis between L-TSA and S-TSA patients. Considering variceal bleedings, our 485 
data are supported by previous reports, in which only the presence of SPSS vs. no 486 
SPSS was shown to be associated with bleeding, but no differences between small 487 
and large SPSS were detected (7,10,15,29). 488 
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Interestingly, the cut-off we found in our patients corresponds to a single shunt of 489 
10mm diameter. In non-spontaneous SPSS, such as TIPS, it has been previously 490 
shown also that small diameter shunts are associated with less hepatic 491 
encephalopathy and survival compared to the usually used 10mm stents (37,38,40). 492 
However, in case of TIPS the collaterals and the other SPSS have been rigorously 493 
embolized in order to limit TSA to 10mm and other persisting collaterals (in many 494 
patients present) may have contributed to non-significant results regarding survival.  495 
This study presents a large, multicentric, international, well characterized cohort of 496 
cirrhotic patients with SPSS. However, it has several limitations, which are mainly 497 
based on the retrospective nature of the study. Some parameters such as endoscopy 498 
and follow up blood work were not available in all patients. Patients were not 499 
specifically screened for non-cirrhotic portal hypertension. Moreover, exploring a 500 
pathophysiological mechanism is beyond the scope of this study. Longitudinal data of 501 
the impact of SPSS on the natural history are needed. Especially, the development of 502 
portal venous thrombosis and its relation to medical treatment, such as non-selective 503 
betablockers and anticoagulants, should be addressed in future longitudinal studies 504 
(41–45). In this study only cirrhotic patients who underwent CT scan were included. 505 
This would lead to a selection bias towards patients without severe kidney 506 
dysfunction because those patients would not receive CT scan due to contrast media 507 
exposure. Moreover, no data on sarcopenia is available, which has recently been 508 
recognized as a risk factor for the development of hepatic encephalopathy after TIPS 509 
(46–50) and could be a competing factor to consider against TSA.  510 
In conclusion, this study for the first time highlights the prognostic importance of TSA 511 
(sum of all cross-sectional SPSS areas) in patients with mostly decompensated liver 512 
cirrhosis. The prevalence of more than one SPSS among these patients is high and 513 
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increases with advancement of liver disease. L-TSA is an independent predictor of 1-514 
year mortality and is associated with higher rates of hepatic encephalopathy 515 
compared to S-TSA. These data suggest that there is a cut-off for portosystemically 516 
shunted blood volume where the beneficial effects get overweighed by the 517 
deleterious ones. Our results may have impact on clinical use of TSA/SPSS for risk 518 
stratification and clinical decision-making considering management of SPSS.  519 
Word count: 3729    520 
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Figure legends:  673 
Figure 1. Flowchart of patient selection.  674 
 675 
Figure 2. a) Cumulative hazard function for the occurrence of overt hepatic 676 
encephalopathy during 1-year follow up in L-TSA (green line) vs. S-TSA (blue line) 677 
patients in training cohort.  b) Cumulative hazard function for the occurrence of overt 678 
hepatic encephalopathy during 1-year follow up in L-TSA (green line) vs. S-TSA (blue 679 
line) patients in validation cohort.  (S-/L-TSA: small (<83mm2) / large (≥83mm2) total 680 
SPSS area). Statistical analysis: log rank test. 681 
 682 
Figure 3. a) Kaplan-Meier curve showing impaired 1-year survival in L-TSA patients 683 
(green line) compared to S-TSA patients (blue line) in training cohort. b) Kaplan-684 
Meier curve showing impaired 1-year survival in L-TSA patients (green line) 685 
compared to S-TSA patients (blue line) in validation cohort. (S-/L-TSA: small 686 
(<83mm2) / large (≥83mm2) total SPSS area). Statistical analysis: log rank test. 687 
 688 
Table 1. General characteristics of the training cohort (n=301). 
 
 
 
 
 
MELD – model of end-stage liver disease, CLIF-C AD – Chronic Liver Failure Consortium Acute Decompensation, 
AST – Aspartate Aminotransferase, ALT – Alanine Aminotransferase, INR – international normalized ratio, WBC – 
White Blood Cell Count; *p<0.05; **p<0.01; ***p<0.001 
 
 
 
 
  
 
Parameter History Baseline Follow Up 
  median (range) or absolute (percentage)    
  
G
en
er
al
 
Age [years] 58 (28-85)   
Gender [male/female] 169/132 (56/44%)   
Etiology of cirrhosis [alcohol, viral, other] 173/60/68 (57/20/23%)   
Number of shunts [1/2/3] 213/86/2 (71/29/1%)   
Total Shunt Area [mm2] 59 (6-881)   
 
Cl
in
ic
a
l E
v
en
ts
 
Ascites 143 (48%) 194 (64%) 116 (53%) 
Variceal Bleeding 85 (28%) 48 (16%) 29 (13%) 
Spontaneous Bacterial Peritonitis 20 (7%) 32 (11%) 20 (9%) 
Hepatorenal Syndrome 30 (10%) 49 (16%) 50 (23%)*** 
Hepatic Encephalopathy  47 (16%) 78 (26%) 84 (38%)*** 
 
Sc
o
re
s
 
MELD 13 (6-40) 12.5 (6-40)* 
MELD-Na 15 (6-40) 14 (6-40) 
Child-Pugh 7 (5-13) 7 (5-12) 
Child-Pugh class A / B / C 103/143/34 (34/48/11%) 90/68/32 (41/31/15%) 
CLIF-C AD 20.65 (10-29) 20.58 (9-32) 
 
La
bo
ra
to
ry
 
Sodium [mmol/l]   138 (119-154) 140 (119-163)*** 
Creatinine [mg/dl]   0.97 (0.3-6.04) 1 (0.1-9.39)*** 
Bilirubin [mg/dl]   1.86 (0.21-48.44) 1.75 (0.19-42.49) 
AST [U/l]   52 (12-653) 44.5 (9-5644) 
ALT [U/l]   31 (8-349) 33 (6-1952) 
Albumin [g/l]   29.2 (3.2-59.9) 32.8 (3.2-55)*** 
INR   1.2 (0.9-4.6) 1.2 (0.9-5.3) 
WBC [10³/µl]   5.86 (1.02-37.17) 5.795 (0.04-36.22) 
Platelets [x109/L]   105.5 (11-653) 107.5 (14-479) 
Table 2. General characteristics of external validation cohort (n=607). 
 
 
 
 
 
MELD – model of end-stage liver disease, CLIF-C AD – Chronic Liver Failure Consortium Acute Decompensation, 
AST – Aspartate Aminotransferase, ALT – Alanine Aminotransferase, INR – international normalized ratio, WBC – 
White Blood Cell Count; *p<0.05; **p<0.01; ***p<0.001 
  
 
 Parameter History Baseline Follow Up 
  
median (range) or absolute (percentage)    
  
G
en
er
al
 
Age [years] 58(18-87) 
  
Sex male / female 397/210 (65/35%) 
  
Etiology of cirrhosis alcohol / viral / others 259/164/184(43/27/30%) 
  
Number of Shunts 1/2/3/4 480/110/14/3(79/18/2/1%) 
  
Total Shunt Area [mm2] 79(13-2205) 
  
 
Cl
in
ic
a
l E
v
en
ts
 
Ascites 345(58%) 321(53%) 341(57%) 
Variceal Bleeding 151(25%) 65(11%) 96(16%) 
Spontaneous Bacterial Peritonitis 65(11%) 39(7%) 72(12%) 
Hepatorenal Syndrome 18(3%) 23(4%) 63(11%)*** 
Hepatic Encephalopathy 183(30%) 152(25%) 247(42%)*** 
 
Sc
o
re
s
 
MELD 13(6-37) 
  
MELD-Na 15(6-40) 
  
Child-Pugh 8(5-15) 
  
Child-Pugh class A / B / C 195/238/147(34/41/25%) 
  
 
La
bo
ra
to
ry
 
Sodium [mmol/l]   138(95-164)   
Creatinine [mg/dl]   0.8(0.3-9.2)   
Bilirubin [mg/dl]   1.8(0.1-45.2)   
Albumin [g/l]   32(10-50)   
INR   1.4(0.9-5.2)   
Platelets [x109/L]   87(13-436)   
Table 3. Clinical and laboratory characteristics of training cohort stratified for total shunt area. 
 
 
  
Parameter S-TSA L-TSA 
  
median (range) or absolute (percentage)   n= 180 n= 121 
Ba
se
 
G
en
er
al
 
Age [years] 57 (28-85) 58 (31-78) 
Sex male / female 99/81 (55/45%) 70/51 (58/42%) 
Etiology of cirrhosis alcohol / viral / others 103/41/36 (57/23/20%) 70/19/32 (58/16/26%) 
Number of Shunts 1/2/3 162/18/0 (90/10/0%) 51/68/2 (42/56/2%)*** 
Total Shunt Area [mm2] 34.72 (5.72-82.34) 141.46 (83.29-880.65)*** 
Hi
st
o
ry
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites  89 (49%) 54 (45%) 
Variceal Bleeding 48 (27%) 37 (31%) 
Spontaneous Bacterial Peritonitis 12 (7%) 8 (7%) 
Hepatorenal Syndrome 19 (11%) 11 (9%) 
Hepatic Encephalopathy  22 (12%) 25 (21%)* 
Ba
se
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites 126 (70%) 68 (56%)* 
Variceal Bleeding 34 (19%) 14 (12%) 
Spontaneous Bacterial Peritonitis 18 (10%) 14 (12%) 
Hepatorenal Syndrome 26 (14%) 23 (19%) 
Hepatic Encephalopathy 42 (23%) 36 (30%) 
Ba
se
 
Sc
o
re
s MELD 11 (6-35) 14 (6-40)*** 
MELD-Na 14 (6-36) 16 (6-40)** 
Child-Pugh 7 (5-11) 7 (5-13) 
Child-Pugh class A / B / C 63/91/13 (35/51/7%) 40/52/21 (33/43/17%) 
Ba
se
 
La
bo
ra
to
ry
 
 Sodium [mmol/l] 138 (119-148) 139 (122-154) 
Creatinine [mg/dl] 0.96 (0.3-6.04) 0.99 (0.42-5.09) 
Bilirubin [mg/dl] 1.56 (0.21-19.9) 2.45 (0.26-48.44)*** 
Albumin [g/l] 29.4 (3.2-51.6) 28.9 (4.8-59.9) 
INR 1.2 (0.9-2.8) 1.3 (1-4.6)*** 
  
Parameter S-TSA L-TSA 
  
 median (range) or absolute (percentage) n=180 n=121 
Fo
llo
w
 
Up
 
Survival FU 1 year [months] 12 (0-12) 8.5 (0-12)* 
FU State 1 year Dead / LT 22 / 9 (17%) 29 /10 (32%)** 
Lost to Follow Up 36 (20%) 23 (19%) 
FU
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites  76 (55%) 40 (49%) 
Variceal Bleeding 22 (16%) 7 (9%) 
Spontaneous Bacterial Peritonitis 14 (10%) 6 (7%) 
Hepatorenal Syndrome  33 (24%) 17 (21%) 
Hepatic Encephalopathy  46 (33%) 38 (47%)* 
FU
 
Sc
o
re
s 
MELD 12 (6-40) 15 (6-40) ** 
MELD-Na 13 (6-40) 16 (6-40)* 
Child-Pugh 6 (5-12) 7 (5-12)* 
Child-Pugh class A / B / C 63/41/14 (46/30/10%) 27/27/18 (33/33/22%)* 
        
 
 
MELD – model of end-stage liver disease, CLIF-C AD – Chronic Liver Failure Consortium Acute Decompensation, 
AST – Aspartate Aminotransferase, ALT – Alanine Aminotransferase, INR – international normalized ratio, WBC – 
White Blood Cell Count, FU – follow up, LT – liver transplantation; *p<0.05; **p<0.01; ***p<0.001 
 
Table 4. Clinical and laboratory characteristics of validation cohort stratified for total shunt area. 
 
 
 
  
Parameter S-TSA L-TSA 
  
median (range) or absolute (percentage)  n= 312 n= 295 
Ba
se
 
G
en
er
al
 
Age [years] 59(18-87) 57(20-84) 
Sex male / female 209/103(67/33%) 188/107(64/36%) 
Etiology of cirrhosis alcohol / viral / others 129/86/97(41/28/31%) 130/78/87(44/26/30%) 
Number of Shunts 1/2/3/4 283/27/2/0(91/8/1/0%) 67/28/12/3(67/28/4/1%)*** 
Total Shunt Area [mm2] 38(13-79) 201(89-2205)*** 
Hi
st
o
ry
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites 180(58%) 165(57%) 
Variceal Bleeding 75(25%) 76(26%) 
Spontaneous Bacterial Peritonitis 37(12%) 28(10%) 
Hepatorenal Syndrome 9(3%) 9(3%) 
Hepatic Encephalopathy 71(23%) 112(38%)*** 
Ba
se
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites 176(56%) 145(49%) 
Variceal Bleeding 42(14%) 23(8%)* 
Spontaneous Bacterial Peritonitis 22(7%) 17(6%) 
Hepatorenal Syndrome 15(5%) 8(3%) 
Hepatic Encephalopathy 64(21%) 88(30%)** 
Ba
se
 
Sc
o
re
s MELD 12(6-37) 14(6-33)** 
MELD-Na 15(6-37) 15(6-40) 
Child-Pugh 8(5-15) 8(5-15)* 
Child-Pugh class A / B / C  109/120/73(36/40/24%) 86/118/74(31/42/27%) 
Ba
se
 
La
bo
ra
to
ry
 
 Sodium [mmol/l] 137(117-164) 138(95-148) 
Creatinine [mg/dl] 0.8(0.3-3.8) 0.8(0.4-9.2) 
Bilirubin [mg/dl] 1.5(0.1-42.9) 2.1(0.3-45.2)* 
Albumin [g/l] 32(10-50) 32(15-50) 
INRf 1.4(0.9-5.2) 1.4(1.0-4.1) 
      
  
Parameter S-TSA L-TSA 
  
 median (range) or absolute (percentage) n= 312 n= 295 
Fo
llo
w
 
Up
 
Survival FU 1 year [months] 12(0-12) 11(0-12)* 
FU State 1 year Dead /  LT 45/28 (23%) 78/31 (37%)*** 
Lost to Follow Up  42(13%) 56(19%) 
FU
 
Cl
in
ic
al
 
Ev
en
ts
 
Ascites 182(59%) 159(56%) 
Variceal Bleeding 55(18%) 41(14%) 
Spontaneous Bacterial Peritonitis 37(12%) 35(12%) 
Hepatorenal Syndrome 34(11%) 29(10%) 
Hepatic Encephalopathy 107(35%) 140(49%)*** 
      
MELD – model of end-stage liver disease, CLIF-C AD – Chronic Liver Failure Consortium Acute Decompensation, 
AST – Aspartate Aminotransferase, ALT – Alanine Aminotransferase, INR – international normalized ratio, WBC – 
White Blood Cell Count, FU – follow up, LT – liver transplantation; *p<0.05; **p<0.01; ***p<0.001 
 
 
 
 
 
 
 
Table 5. Univariate and multivariate Cox regression analysis of training cohort with 1-year mortality as endpoint. 
 
 
 
 
 
1-[years], 2- [mmol/l], 3-[mg/dl] 
Italic – included in multivariate analysis, Bold – significant in multivariate analysis 
MELD – model of end-stage liver disease, INR – international normalized ratio, L-TSA – large Total Shunt Area, SBP 
– spontaneous bacterial peritonitis,  
 
  
1-year mortality  univariate Cox regression multivariate Cox regression 
Parameter p HR CI p HR CI 
age1 0.025 1.027 1.003 1.051 <0.001 1.060 1.031 1.089 
sex 0.332             
L-TSA 0.001 2.266 1.407 3.650 0.040 1.660 1.023 2.695 
hepatic encephalopathy at baseline <0.001 3.519 2.190 5.657 0.002 2.204 1.342 3.619 
hepatorenal syndrome at baseline <0.001 5.781 3.561 9.386 0.024 1.890 1.088 3.283 
ascites at baseline 0.002 2.566 1.427 4.615 0.507     
SBP at baseline 0.001 2.736 1.541 4.857 0.693     
MELD at baseline <0.001 1.180 1.144 1.217 <0.001 1.175 1.129 1.222 
sodium at baseline2 0.022 0.950 0.909 0.993         
creatinine at baseline3 <0.001 2.171 1.783 2.643         
bilirubin at baseline3 <0.001 1.122 1.092 1.153         
INR at baseline <0.001 4.469 3.221 6.202         
Table 6. Univariate and multivariate Cox regression analysis of validation cohort with 1-year mortality as endpoint. 
 
 
 
 
1-[years], 2- [mmol/l], 3-[mg/dl] 
Italic – included in multivariate analysis, Bold – significant in multivariate analysis 
 
MELD – model of end-stage liver disease, INR – international normalized ratio, L-TSA – large Total Shunt Area, SBP 
– spontaneous bacterial peritonitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-year mortality  univariate Cox regression multivariate Cox regression 
Parameter p HR CI p HR CI 
age1 0.148     0.004 1.020 1.006 1.034 
sex 0.040 1.407 1.016 1.947         
L-TSA <0.001 1.724 1.276 2.330 <0.001 2.220 1.612 3.005 
hepatic encephalopathy at baseline <0.001 2.109 1.547 2.875 0.268     
hepatorenal syndrome at baseline <0.001 4.998 2.885 8.658 0.014 2.222 1.172 4.214 
ascites at baseline <0.001 2.928 2.105 4.072 <0.001 2.054 1.434 2.941 
SBP at baseline <0.001 2.811 1.763 4.481 0.454     
MELD at baseline <0.001 1.130 1.104 1.156 <0.001 1.112 1.081 1.143 
sodium at baseline2 <0.001 0.943 0.924 0.961         
creatinine at baseline3 <0.001 1.870 1.560 2.242         
bilirubin at baseline3 <0.001 1.071 1.046 1.097         
INR at baseline <0.001 2.047 1.693 2.475         
Figure 1.
Training cohort
301 cirrhotic patients with SPSS and CT scan
(University of Bonn)
Total 908 cirrhotic patients with SPSS and CT
Validation cohort
607 cirrhotic patients with SPSS and CT scan
(multicentric international)
Establishment of TSA
S-TSA (n=180)
Follow Up
1-year mortality: 17%
HE: 33%
L-TSA (n=121)
Follow Up
1-year mortality: 32%
HE: 47%
S-TSA (n=312)
Follow Up
1-year mortality: 23%
HE: 35%
L-TSA (n=295)
Follow Up
1-year mortality: 37%
HE: 49%
Figure 2 
p<0.01p<0.01
Patients at risk
S-TSA 304 257 240 212 190
L-TSA 284 242 222 198 169
Patients at risk
S-TSA 137 120 106 98 89
L-TSA 81 73 58 49 44
A B
Figure 3
p<0.001 p<0.001
Patients at risk
S-TSA 312 260 243 215 193
L-TSA 292 239 206 168 127
Patients at risk
S-TSA 153 120 106 97 85
L-TSA 100 72 57 47 39
A B
HIGHLIGHTS: 
 
- Total cross-sectional area of spontaneous portosystemic shunt (SPSS), rather 
than diameter of the single largest SPSS, predicts survival in patients with 
advanced chronic liver disease.  
- The cut-off of the total cross-sectional SPSS area associated with worse 
survival corresponds to a single shunt of more than 10mm diameter.  
- This study may have impact on clinical use of TSA/SPSS for risk stratification 
and clinical decision-making considering management of SPSS.  
 
